Cargando…
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649441/ http://dx.doi.org/10.1186/2051-1426-3-S2-P376 |
| _version_ | 1782401358820802560 |
|---|---|
| author | Taylor, Matthew Antonia, Scott Bendell, Johanna Calvo, Emiliano Jäger, Dirk de Braud, Filippo Ott, Patrick A Pietanza, M Catherine Horn, Leora Le, Dung T Morse, Michael A López-Martin, José A Ascierto, Paolo A Christensen, Olaf Simon, Jason S Lin, Chen-Sheng Eder, Joseph Paul |
| author_facet | Taylor, Matthew Antonia, Scott Bendell, Johanna Calvo, Emiliano Jäger, Dirk de Braud, Filippo Ott, Patrick A Pietanza, M Catherine Horn, Leora Le, Dung T Morse, Michael A López-Martin, José A Ascierto, Paolo A Christensen, Olaf Simon, Jason S Lin, Chen-Sheng Eder, Joseph Paul |
| author_sort | Taylor, Matthew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4649441 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46494412015-11-24 Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 Taylor, Matthew Antonia, Scott Bendell, Johanna Calvo, Emiliano Jäger, Dirk de Braud, Filippo Ott, Patrick A Pietanza, M Catherine Horn, Leora Le, Dung T Morse, Michael A López-Martin, José A Ascierto, Paolo A Christensen, Olaf Simon, Jason S Lin, Chen-Sheng Eder, Joseph Paul J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4649441/ http://dx.doi.org/10.1186/2051-1426-3-S2-P376 Text en Copyright © 2015 Taylor et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Taylor, Matthew Antonia, Scott Bendell, Johanna Calvo, Emiliano Jäger, Dirk de Braud, Filippo Ott, Patrick A Pietanza, M Catherine Horn, Leora Le, Dung T Morse, Michael A López-Martin, José A Ascierto, Paolo A Christensen, Olaf Simon, Jason S Lin, Chen-Sheng Eder, Joseph Paul Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 |
| title | Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 |
| title_full | Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 |
| title_fullStr | Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 |
| title_full_unstemmed | Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 |
| title_short | Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 |
| title_sort | phase i/ii study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (sclc): ca209-032 |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649441/ http://dx.doi.org/10.1186/2051-1426-3-S2-P376 |
| work_keys_str_mv | AT taylormatthew phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT antoniascott phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT bendelljohanna phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT calvoemiliano phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT jagerdirk phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT debraudfilippo phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT ottpatricka phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT pietanzamcatherine phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT hornleora phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT ledungt phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT morsemichaela phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT lopezmartinjosea phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT asciertopaoloa phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT christensenolaf phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT simonjasons phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT linchensheng phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 AT ederjosephpaul phaseiiistudyofnivolumabwithorwithoutipilimumabfortreatmentofrecurrentsmallcelllungcancersclcca209032 |